# US 2008/0306154 A1 · Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306154 A1
- Document ID: US20080306154A1
- Status: Published application
- Kind: A1
- Application number: 11/979,540
- Filed: 2007-11-05
- Published: 2008-12-11
- Earliest claimed: 2006-11-03
- Inventors: My Svensson; Jeppe Hagstrup Christensen; Erik Berg Schmidt; Kaj Anker Jorgensen
- Web page: https://patentgrep.com/patent/US20080306154A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and/or diabetes.

## Claims

### Claim 1

A method of reducing the occurrence of or preventing a major adverse cardiovascular event (MACE) or major coronary event (MCE) in a patient who has established cardiovascular disease without prior myocardial infarction, comprising the steps of:
providing an omega-3 fatty acid composition comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); and
administering the composition to the patient in an amount effective to reduce the occurrence of or prevent a MACE or an MCE.

### Claim 2

A method of treating CVD in a patient who has established cardiovascular disease without prior myocardial infarction, comprising the steps of
providing an omega-3 fatty acid composition comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); and
administering the composition to the patient in an amount effective to treat CVD.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method provides an effective treatment for underlying conditions or risk factors of major adverse cardiovascular events or major coronary events.

### Claim 4 (depends on 2)

The method of claim 2, wherein the method reduces the occurrence of or prevents the occurrence of a major adverse cardiovascular event or major coronary event in a patient who has established cardiovascular disease without prior myocardial infarction.

### Claim 5 (depends on 4)

The method of claim 4, wherein the major coronary event is selected from the group consisting of myocardial infarctions; and coronary interventions selected from the group consisting of coronary revascularization, investigational or interventional angioplasty, percutaneous transluminal coronary angioplasty, percutaneous coronary intervention, and coronary artery bypass graft.

### Claim 6 (depends on 2)

The method of claim 2, wherein the method reduces the occurrence of or prevents myocardial infarction in a patient who has established cardiovascular disease without prior myocardial infarction.

### Claim 7 (depends on 2)

The method of claim 2, wherein the method provides an effective treatment for conditions selected from the group consisting of hypertension, dyslipidemia, obesity, and diabetes.

### Claim 8 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises omega-3 fatty acids present in a concentration of at least 40% by weight as compared to the total fatty acid content of the composition.

### Claim 9 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises omega-3 fatty acids present in a concentration of at least 80% by weight as compared to the total fatty acid content of the composition.

### Claim 10 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises at least 50% by weight of EPA and DHA as compared to the total fatty acid content of the composition.

### Claim 11 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises at least 80% by weight of EPA and DHA as compared to the total fatty acid content of the composition.

### Claim 12 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises about 5% to about 95% by weight of EPA as compared to the total fatty acid content of the composition.

### Claim 13 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises about 40% to about 55% by weight of EPA as compared to the total fatty acid content of the composition.

### Claim 14 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises about 5% to about 95% by weight of DHA as compared to the total fatty acid content of the composition.

### Claim 15 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises about 30% to about 60% by weight of DHA as compared to the total fatty acid content of the composition.

### Claim 16 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition is provided as a daily dose of from about 1.5 to about 4 grams per day.

### Claim 17 (depends on 20)

The method of claim 20, wherein the omega-3 fatty acid composition is provided in a daily dose of about 2 grams per day.

### Claim 18 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition comprises omega-3 fatty acids selected from the group consisting of omega-3 polyunsaturated, long-chain fatty acids; esters of omega-3 fatty acids with glycerol; esters of omega-3 fatty acids and a primary, secondary or tertiary alcohol; and mixtures thereof.

### Claim 19 (depends on 2)

The method of claim 2, wherein the EPA and DHA are in a weight ratio of EPA:DHA of from 4:1 to 1:4.

### Claim 20 (depends on 2)

The method of claim 2, wherein the EPA and DHA are in a weight ratio of EPA:DHA of from 1:2 to 2:1.

### Claim 21 (depends on 2)

The method of claim 2, wherein the omega-3 fatty acid composition is provided for co-administration with one or more additional compounds selected from the group consisting of angiotensin-converting-enzyme inhibitors; angiotensin receptor blockers; renin inhibitors; HMG CoA reductase inhibitors; dihydropyridine calcium channel blockers; antiarrhythmic agents; azetidinone-based cholesterol absorption inhibitors; niacin and derivatives; PPAR agonists/antagonists; bile acid sequestrants; antiplatelet drugs; and pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the omega-3 fatty acid composition is administered apart from administration of the one or more additional compounds.

### Claim 23 (depends on 21)

The method of claim 21, wherein the omega-3 fatty acid composition is administered simultaneous to the administration of the one or more additional compounds.

### Claim 24 (depends on 21)

The method of claim 21, wherein the omega-3 fatty acid composition and the one or more additional compounds are administered in a concomitant treatment regime.

### Claim 25 (depends on 21)

The method of claim 21, wherein the omega-3 fatty acid composition and the one or more additional compounds are administered together in a unit dose form.
